Trethera Corp
Los Angeles, CA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 13451 Rand Dr, Sherman Oaks, CA 91423, USA
- Website
- trethera.com
- Founded
- 2013
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Creative Biotherapeutics LLC | Gurnee, IL | — |
| Thetis Pharmaceuticals LLC | Deep River, CT | — |
| Cartesian Therapeutics Inc. | Frederick, MD | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Seak Therapeutics, LLC | Memphis, TN | — |
| Senex Biotechnology Inc. | Maynard, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Trethera Corp is a clinical-stage biopharmaceutical company located in Sherman Oaks, California, focused on developing innovative small molecule drug therapies targeting the nucleoside salvage pathway. The company specializes in researching and developing targeted pharmaceutical interventions for various autoimmune and cancer-related conditions, with a particular emphasis on developing a novel small molecule inhibitor called TRE-515. Registered in SAM.gov since February 2020, Trethera Corp is a for-profit corporate entity that has successfully secured multiple federal research grants to advance its therapeutic research and development efforts.
Through its federal grant awards, Trethera Corp has been actively pursuing research across multiple medical domains, primarily focusing on developing TRE-515 as a potential treatment for various complex medical conditions. The company has received significant funding from federal agencies including the National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, and the National Eye Institute. Its grant-funded research spans critical areas such as non-small cell lung cancer, castration-resistant prostate cancer, systemic lupus erythematosus, Crohn's disease, acute disseminated encephalomyelitis, and optic neuritis. The grants, ranging from approximately $406,500 to $1,150,000, support preclinical studies, translational research, and potential clinical advancement of TRE-515, with a consistent focus on targeting the deoxycytidine kinase (DCK) enzyme to selectively inhibit lymphocyte proliferation and address underlying disease mechanisms.
Quick answers
Is Trethera Corp registered in SAM.gov?
Yes. Trethera Corp's SAM.gov registration is active through April 16, 2027.
What is Trethera Corp's CAGE code?
Trethera Corp's CAGE code is 7NJ74, and its Unique Entity ID (UEI) is QB66ZMAUF5P7.
What is Trethera Corp's most recent federal award?
Trethera Corp's most recent federal grant award is Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through murine studies to… (R44CA306475), from National Cancer Institute (NIH), on September 8, 2025.
On GovTribe
See Trethera Corp's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors